Associations - MYC (V-myc avian myelocytomatosis viral oncogene homolog)

BCL2 expression + MYC expression	Diffuse Large B Cell Lymphoma	BCL2 expression + MYC expression	Diffuse Large B Cell Lymphoma	chidamide Sensitive: A1 - Approval chidamide Sensitive : A1	chidamide Sensitive: A1 - Approval chidamide Sensitive : A1
MYC rearrangement + BCL6 rearrangement	Diffuse Large B Cell Lymphoma	MYC rearrangement + BCL6 rearrangement	Diffuse Large B Cell Lymphoma	lisocabtagene maraleucel Sensitive: A2 - Guideline lisocabtagene maraleucel Sensitive : A2	lisocabtagene maraleucel Sensitive: A2 - Guideline lisocabtagene maraleucel Sensitive : A2
MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement	Diffuse Large B Cell Lymphoma	MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement	Diffuse Large B Cell Lymphoma	lisocabtagene maraleucel Sensitive: A2 - Guideline lisocabtagene maraleucel Sensitive : A2	lisocabtagene maraleucel Sensitive: A2 - Guideline lisocabtagene maraleucel Sensitive : A2
MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma	MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma	lisocabtagene maraleucel Sensitive: A2 - Guideline lisocabtagene maraleucel Sensitive : A2	lisocabtagene maraleucel Sensitive: A2 - Guideline lisocabtagene maraleucel Sensitive : A2
MYC overexpression + BCL2 overexpression	Diffuse Large B Cell Lymphoma	MYC overexpression + BCL2 overexpression	Diffuse Large B Cell Lymphoma	ibrutinib Sensitive: B - Late Trials ibrutinib Sensitive : B	ibrutinib Sensitive: B - Late Trials ibrutinib Sensitive : B
MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma	MYC rearrangement + BCL2 rearrangement	Diffuse Large B Cell Lymphoma	lenalidomide Sensitive: B - Late Trials lenalidomide Sensitive : B	lenalidomide Sensitive: B - Late Trials lenalidomide Sensitive : B
MYC rearrangement	Diffuse Large B Cell Lymphoma	MYC rearrangement	Diffuse Large B Cell Lymphoma	lenalidomide Sensitive: B - Late Trials lenalidomide Sensitive : B	lenalidomide Sensitive: B - Late Trials lenalidomide Sensitive : B
MYC amplification	Non Small Cell Lung Cancer	MYC amplification	Non Small Cell Lung Cancer	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B
BCL2 overexpression + MYC overexpression	Diffuse Large B Cell Lymphoma	BCL2 overexpression + MYC overexpression	Diffuse Large B Cell Lymphoma	ibrutinib Sensitive: B - Late Trials ibrutinib Sensitive : B	ibrutinib Sensitive: B - Late Trials ibrutinib Sensitive : B
MYC amplification	Small Cell Lung Cancer	MYC amplification	Small Cell Lung Cancer	AZD1775 Sensitive: C2 – Inclusion Criteria AZD1775 Sensitive : C2	AZD1775 Sensitive: C2 – Inclusion Criteria AZD1775 Sensitive : C2
MYC expression	Diffuse Large B Cell Lymphoma	MYC expression	Diffuse Large B Cell Lymphoma	RG6146 Sensitive: C2 – Inclusion Criteria RG6146 Sensitive : C2	RG6146 Sensitive: C2 – Inclusion Criteria RG6146 Sensitive : C2
MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement	Lymphoma	MYC rearrangement + BCL2 rearrangement + BCL6 rearrangement	Lymphoma	lisocabtagene maraleucel Sensitive: C2 – Inclusion Criteria lisocabtagene maraleucel Sensitive : C2	lisocabtagene maraleucel Sensitive: C2 – Inclusion Criteria lisocabtagene maraleucel Sensitive : C2

MYC (V-myc avian myelocytomatosis viral oncogene homolog)

Associations(180)

Associations
(180)